A Prospective Randomized Multicenter Study of Flecainide Acetate Oral Inhalation Solution in Single and Repeat Dose Regimens for Acute Conversion to Sinus Rhythm in Subjects With Recent Onset of Symptomatic Paroxysmal Atrial Fibrillation
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Flecainide (Primary)
- Indications Paroxysmal atrial fibrillation
- Focus Therapeutic Use
- Acronyms INSTANT
- Sponsors InCarda Therapeutics
- 08 Nov 2018 Planned number of patients changed from 110 to 140.
- 19 Jun 2018 Status changed from not yet recruiting to recruiting.
- 01 Jun 2018 New trial record